Inicio・Lista de Acciones・Alvotech SA

Alvotech SA

Abierto

SectorSanidad

4.05 -0.74

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.98

Máximo

4.13

Métricas clave
By Trading Economics
Ingresos	110M 1M
Ventas	-60M 106M
P/B Media del Sector	42.4 57.002
BPA	-0.09
Margen de beneficios	0.973
Empleados	1,279
EBITDA	167M 52M

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 Meses	-2.2% downside

Dividendos
By Acuity
Próximas Ganancias	19 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	261M 1.3B
Apertura anterior	4.79
Cierre anterior	4.05

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

134 / 340 Clasificación en Healthcare

Alvotech SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12 ago 2026, 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11 ago 2026, 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10 ago 2026, 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6 ago 2026, 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5 ago 2026, 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4 ago 2026, 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3 ago 2026, 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

31 jul 2026, 21:02 UTC

Alvotech SA shares declined in after-market trading, reversing six days of gains. No specific news was identified to explain the price movement.

30 jul 2026, 20:10 UTC

Alvotech SA shares are higher during Thursday's session, reflecting broader market movements amid mixed economic signals and maintaining a position above the 20-day moving average.

29 jul 2026, 19:04 UTC

News

Social Media

Alvotech SA's FDA inspection results in a Voluntary Action Indicated classification. Shares are trading higher as the company advances its biosimilar pipeline.

28 jul 2026, 19:56 UTC

Alvotech SA shares are higher today, reaching a high of 6.17%. The stock remains below its 20-day moving average with no specific news identified.

27 jul 2026, 19:31 UTC

Alvotech SA shares are higher today, rebounding from an earlier session low. This follows a positive trend since Friday's close amid declining oil prices.

24 jul 2026, 19:51 UTC

Alvotech SA shares are lower today, continuing a trend of weakness amid broader market pressures and three consecutive lower daily closes.

22 jul 2026, 18:31 UTC

Alvotech SA shares are lower, continuing a decline since Tuesday. Broader market sentiment is impacted by geopolitical tensions and rising crude oil prices.

21 jul 2026, 19:16 UTC

Alvotech SA shares are higher during Tuesday's session amid a broader market recovery, driven by renewed interest in AI stocks and upcoming tech earnings.

20 jul 2026, 19:31 UTC

Alvotech SA shares are lower today, with no specific news identified. Broader market weakness includes a decline in the US 10Y Treasury Bond index.

Comparación entre iguales

Cambio de precio

Alvotech SA previsión

Precio Objetivo

By TipRanks

-2.2% descenso

Estimación a 12 Meses

Media 4 USD -2.2%

Máximo 4 USD

Mínimo 4 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alvotech SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Alvotech SA Dist en los últimos 3 meses.

Sentimiento

By Acuity

134 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.